SEAVUE

Phase 3b, multicenter, randomized, blinded, active-controlled study to compare the efficacy and safety of Ustekinumab to that of Adalimumab in the treatment of biologic naive subjects with moderately-to-severely active Crohn’s Disease. Safety and efficacy of Humira (Adalimumab) versus Stelara (Ustekinumab) for one year.

Sponsor: Janssen Research & Development

Principal Investigator: Dr. William Holderman

We are looking for patients to participate in this study:

  • Biologic naive moderate to severe Crohn’s Disease diagnosed more than 3 months
  • Failure from previous treatment, inadequate response to or lost response to, or was intolerant to immunomodulators or corticosteroid dependent